AstraZeneca Says Ultomiris Approved in US for Adults With Generalized Myasthenia Gravis
28 April 2022 - 8:43AM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Thursday that Ultomiris has been approved
in the U.S. for the treatment of adult patients with generalized
myasthenia gravis.
The FTSE 100 pharma giant said the approval from the Food and
Drug Administration was based on positive results from a Phase 3
trial which showed the drug was superior to placebo.
Generalized myasthenia gravis is an autoimmune neuromuscular
disease that leads to a loss of muscle function and weakness and
which affects an estimated 90,000 people in the U.S.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
April 28, 2022 02:28 ET (06:28 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
